Sjögren's disease & overlap diseases
CXCL9 may serve as a potential biomarker for primary Sjögren’s syndrome with extra-glandular manifestations
Authors' conclusion
CXCL9 proves to be a valuable biomarker in pSS, specifically due to its strong ability to differentiate between pSS patients with EGM and those without EGM. There is a significant correlation between CXCL9 and various clinical parameters both at the gene and protein level.
Study context
- Population
- Patients with Primary Sjögren's syndrome (pSS) (with and without extra-glandular manifestations (EGM)) and non-pSS individuals; minor salivary gland gene expression profiles
- Exposure
- pSS vs non-pSS individuals; PSS with EGM (pSS-EGM) vs pSS-non-EGM
- pSSn = 63
- non-pSSn = 12reference
- Outcome
- CXCL9 expression: Minor salivary glands (MSG) gene and plasma protein
Methodological detailsRNA sequencing of minor salivary glands, bioinformatics analysis with PPI network, validation in peripheral blood plasma
- RNA sequencing of minor salivary glands
- Bioinformatics analysis with PPI network
- Validation in peripheral blood plasma
Main finding
As reported in the abstract
- 725 differentially expressed genes (DEGs) between pSS and non-pSS
- 727 DEGs between pSS-EGM and pSS-non-EGM
- CXCL9 gene expression and protein levels notably higher in pSS with EGM and in those with SSA antibodies
- CXCL9 gene expression correlated with EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI), immunoglobulin G (IgG) levels and erythrocyte sedimentation rate (ESR)
- CXCL9 protein levels correlated with IgG levels and ESSDAI
- pSS vs non-pSS: P < 0.001
Observational data: associations, not effects.
Original publication
CXCL9 may serve as a potential biomarker for primary Sjögren’s syndrome with extra-glandular manifestations. Arthritis Res Ther. Published 17 January 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →